Carisma Therapeutics’ solid tumour therapy obtains FDA Fast Track status

26 Jun 2024
www.pharmaceutical-technology.com
Fast TrackPhase 1Gene TherapyCell Therapy
Carisma Therapeutics’ solid tumour therapy obtains FDA Fast Track status
Preview
Source: Pharmaceutical Technology
Participants with unresectable or metastatic solid tumours that overexpress HER2 will be part of the Phase I trial. Credit: Vink Fan via Shutterstock.
Carisma Therapeutics’ solid tumour therapy obtains FDA Fast Track status
Preview
Source: Pharmaceutical Technology
The US Food and Drug Administration (FDA) has granted Fast Track designation for Carisma Therapeutics’ CT-0525 for the treatment of solid tumours overexpressing human epidermal growth factor receptor 2 (HER2).
An ex vivo gene-modified autologous chimeric antigen receptor-monocyte cellular therapy, CT-0525 is being analysed in a Phase I clinical trial.
The open-label trial is designed to assess the safety, tolerability, and manufacturing feasibility of the therapy.
Participants enrolled in the trial will include those with locally advanced (unresectable) or metastatic solid tumours that overexpress HER2 and have advanced following treatment with standard therapies approved presently.
The trial will also feature two dose escalation cohorts to determine the optimal dose of CT-0525.
See Also:AstraZeneca’s Tagrisso receives approval in Japan for lung cancer
Carisma Therapeutics’ solid tumour therapy obtains FDA Fast Track status
Preview
Source: Pharmaceutical Technology
AstraZeneca’s Truqap and Faslodex combo receives approval in EU
Carisma Therapeutics’ solid tumour therapy obtains FDA Fast Track status
Preview
Source: Pharmaceutical Technology
With the receipt of FDA Fast Track status, CT-0525 is now poised for an accelerated review process.
Carisma Therapeutics CMO Eugene Kennedy said: “Receiving Fast Track designation for CT-0525 from the FDA marks a significant milestone for Carisma, highlighting the FDA’s recognition of the serious and life-threatening nature of these malignancies and the potential of CT-0525 to meet this critical medical need.
“We are committed to working closely with the FDA to accelerate the development of CT-0525. Currently, we are enrolling patients in the Phase I clinical trial and remain on track to report initial clinical data by the end of 2024.”
This designation is a significant milestone, intended to expedite the development and review of therapies for serious conditions with unmet medical needs.
In 2022, Carisma Therapeutics and Sesen Bio signed a definitive merger agreement to combine businesses and create a clinical-stage biotechnology company in an all-stock deal.
Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.
Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.
Free WhitepaperCell and gene therapies: Pipe dream to pipeline
The cell and gene industry is gaining momentum, with a new wave of therapies promising to transform the way doctors treat, and even cure, disease. In this report, Cytiva and GlobalData have collaborated to explore the rise of the cell and gene therapy industries, the current state of the market, present and future opportunities for advancement, and the challenges that lie ahead.
Thank you.You will receive an email shortly. Please check your inbox to download the Whitepaper.
Carisma Therapeutics’ solid tumour therapy obtains FDA Fast Track status
Preview
Source: Pharmaceutical Technology
-->
By downloading this case study, you acknowledge that GlobalData may share your information with Cytiva Thematic and that your personal data will be used as described in their Privacy Policy
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.